Table 2.
Results on the treatment and outcome of cats with mycobacterial disease. The tissue samples had histopathological changes suggestive of mycobacterial infection and were submitted to the VLA for mycobacterial culture between January 2005 and December 2008. Results shown with prevalence and 95% exact binomial CI, the statistical significance (Wald P-value) and the OR (and 95% CI) for these factors associated with mycobacterium being grown from the samples.
| n | Positive | % | P-value | OR (95% CI) | ||
|---|---|---|---|---|---|---|
|
| ||||||
| Received some treatment | 212 | 184 | 86.8 | (81.4–91.0) | 0.148 | 0.54 (0.24–1.24) |
| Underwent surgery | 177 | 67 | 37.9 | (30.6–45.4) | 0.321 | 0.73 (0.40–1.35) |
| Treated with a drug | 187 | 168 | 89.8 | (84.5–93.8) | 0.112 | 0.44 (0.16–1.21) |
| Macrolide/azalide (eg, clarithromycin/azithromycin) | 169 | 42 | 24.9 | (18.5–32.1) | 0.563 | 1.23 (0.61–2.48) |
| Lincosamide (eg, lincomycin, clindamycin) | 172 | 23 | 13.4 | (8.6–19.4) | 0.122 | 0.49 (0.19–1.21) |
| β-lactam (eg, penicillins, cephalosporins) | 177 | 85 | 48 | (40.4–55.6) | 0.327 | 0.74 (0.41–1.34) |
| Fluoroquinolone (eg, enrofloxacin, marbofloxacin) | 175 | 93 | 53.1 | (45.4–60.7) | 0.943 | 1.02 (0.56–1.85) |
| Tetracycline (eg, doxycycline) | 169 | 9 | 5.3 | (2.4–9.9) | 0.305 | 0.48 (0.11–1.97) |
| Rifampicin | 170 | 35 | 20.6 | (14.7–27.5) | 0.385 | 1.39 (0.66–2.95) |
| Triple therapy (ie, macrolide/azalide + fluoroquinolone + rifampicin) | 168 | 27 | 16.1 | (10.8–22.5) | 0.296 | 1.56 (0.68–3.60) |
| Corticosteroid | 173 | 25 | 14.5 | (9.5–20.6) | 0.243 | 0.60 (0.25–1.42) |
| Duration of treatment | 140 | |||||
| <1 month | 85 | 60.7 | (52.1–68.9) | — | Reference level | |
| 1–6 months | 40 | 28.6 | (21.2–36.8) | 0.184 | 1.67 (0.78–3.57) | |
| ≥6 months | 15 | 10.7 | (6.1–17.1) | 0.538 | 1.41 (0.47–4.25) | |
| Positive response to treatment | 152 | 85 | 55.9 | (47.6–64.0) | 0.337 | 0.73 (0.38–1.39) |
| Complete remission | 78 | 33 | 42.3 | (31.1–54.0) | 0.630 | 1.25 (0.50–1.31) |
| Recurrence of lesion/lump or other clinical signs after treatment (surgery and/or medical management) | 159 | 101 | 63.5 | (55.5–71.0) | 0.674 | 0.87 (0.46–1.66) |
| Progression to respiratory disease, regardless of whether treated or not | 165 | 52 | 0.359 | 0.73 (0.38–1.42) | ||
| Progression to systemic disease, regardless of whether treated or not | 193 | 100 | 31.5 | (24.5–39.2) | 0.364 | 1.30 (0.74–2.29) |